Changsheng Bio-technology Co Ltd operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Changsheng Bio-technology Co Ltd with three other
companies in this sector in China:
Beijing SL Pharmaceutical Co Ltd
sales of 1.01 billion Chinese Renmimbi [US$156.95 million]
of which 98%
was Pharmaceuticals Industry),
Boya Bio-pharmaceutical Group Co Ltd
(946.57 million Chinese Renmimbi [US$147.12 million]
of which 56%
was Blood Plasma), and
Tianjin Ringpu Bio-Technology Co Ltd
(969.68 million Chinese Renmimbi [US$150.71 million]
of which 63%
was Veterinary Biological Products).
During the year ended December of 2016, sales at
Changsheng Bio-technology Co Ltd were 1.02 billion Chinese Renmimbi (US$158.20 million).
increase of 28.0%
versus 2015, when the company's sales were 795.33 million Chinese Renmimbi.
Sales of Vaccine Sales saw an increase
28.5% in 2016, from
789.72 million Chinese Renmimbi to 1.01 billion Chinese Renmimbi.
Not all segments of Changsheng Bio-technology Co Ltd experienced an increase in sales in 2016:
sales of Others fell 49.4% to 2.94 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).